- Clone:
- REA786 | BV10A4H2
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for CD135 (FLT3) Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD135 (FLT3) (REA786) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD135 (FLT3) (REA786). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA786 recognizes the human CD135 antigen, a single-pass type I membrane protein also known as Fms-like tyrosine kinase receptor 3 (FLT3) or fetal liver kinase-2 (FLK-2). CD135 belongs to the same family as FMS, KIT, and the two genes encoding PDGFRα and β. CD135 is normally expressed by hematopoietic stem and progenitor cells and expression is lost as hematopoietic cells differentiate. Although, CD135 expression is usually lost upon hematopoietic stem cell (HSC) differentiation, dendritic cells are an exception, as mature dendritic cells (DCs) display persistent FLT3 expression. CD135 is also expressed on malignant hematopoietic cells including AML, ALL, and CML-BC. All hematopoietic cells develop from CD135 negative hematopoietic stem cells through CD135 positive progenitor cells. In synergy with other growth factors like G-CSF, GM-CSF, SCF, and IL-3, ligation of CD135 with FLT3 ligand promotes the differentiation, proliferation, and survival of hematopoietic progenitor cells and of dendritic cells. As a result early B cell lineage differentiation as well as expansion of monocytes and immature dendritic cells are stimulated.
Additional information: Clone REA786 displays negligible binding to Fc receptors.
FLT3, FLK-2, STK-1
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Small, D. et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. U.S.A. 91 (2): 459-463
- Rosnet, O. et al. (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10 (2): 238-248
- Leung, A. Y. et al. (2013) FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia 27 (2): 260-268
You have previously chosen International as your location.
What do you want to do?